Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is... It is being developed by Theravance.
- Mechanism
- Curator reviewed
Velusetrag is a potent, highly selective agonist with high intrinsic activity at the 5-HT4 receptor. Relative to other 5-HT receptor types, Velusetrag is > 500-fold selective for binding to the human 5-HT4 receptor. Theravance anticipates that the high degree of selectivity of Velusetrag provides the potential for it to be a better and safer medicine for the treatment of patients with severe constipation and possibly constipation predominant irritable bowel syndrome.
- Formula / weight
- C25H36N4O5S · 504.65 g/mol (avg)
- Code names
- TD-5108
Resolves to
HXLOHDZQBKCUCR-WOZUAGRISA-NSMILESCC(C)N1C(=O)C(=CC2=CC=CC=C12)C(=O)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C[C@@H](O)CN(C)S(C)(=O)=OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Velusetrag, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account